Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
A third-party industry news report relevant to peptide, incretin, or obesity-drug development. Follow the original source link and verify scientific claims against primary research, trial registries, or regulator records.
Open original source ↗Collected Nov 6, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.